



CS/NSE&BSE/UFR/2015-16
February 12, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN–EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter and nine months ended 31st December, 2015

.....
With reference to the above subject, pursuant to Regulation 33 read with regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. **Friday, 12th February, 2016**, has taken on record the Standalone **Un-audited Financial Results of the Company for the quarter and nine months ended 31st December, 2015**.

We are enclosing herewith the Un-audited Financial Results for the quarter and nine months ended 31st December, 2015 along with **Limited Review Report of Statutory Auditors of the Company**.

Please find enclosed **Press release** of our company. We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read 'K Hanumantha Rao'.

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Nine months ended		Previous year ended
		31-Dec-2015	30-Sep-2015	31-Dec-2014	31-Dec-2015	31-Dec-2014	31-Mar-2015
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	11,250.43	11,676.14	12,882.97	33,024.71	41,019.25	52,085.50
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net) (a)+(b)	11,250.43	11,676.14	12,882.97	33,024.71	41,019.25	52,085.50
2	Expenses						
	a) Cost of materials consumed	4,180.63	5,131.75	4,413.80	13,181.02	13,177.17	17,724.78
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(413.63)	(1,692.51)	(1,020.96)	(3,130.29)	1,009.23	347.95
	d) Employee benefits expense	1,158.02	1,107.57	963.42	3,219.81	2,655.98	3,651.16
	e) Depreciation and amortisation expense	451.96	449.80	290.82	1,192.22	910.58	1,177.58
	f) Other expenses - Manufacturing Expenses	1,799.32	1,921.74	1,812.03	5,283.51	4,804.49	6,444.21
	- R & D Expenses	1,516.96	1,506.29	1,469.96	4,616.85	4,058.80	5,596.26
	- Others	545.58	628.02	602.51	1,813.07	1,639.47	2,375.29
	Total expenses	9,238.84	9,052.66	8,531.58	26,176.19	28,255.72	37,317.23
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	2,011.59	2,623.48	4,351.39	6,848.52	12,763.53	14,768.27
4	Other Income	397.00	578.73	227.13	1,483.27	477.05	858.12
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	2,408.59	3,202.21	4,578.52	8,331.79	13,240.58	15,626.39
6	Finance costs	153.86	139.52	100.55	385.62	349.96	470.92
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	2,254.73	3,062.69	4,477.97	7,946.17	12,890.62	15,155.47
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7+8)	2,254.73	3,062.69	4,477.97	7,946.17	12,890.62	15,155.47
10	Tax Expenses	482.80	589.83	1,255.31	1,678.31	3,710.49	4,280.44
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	1,771.93	2,472.86	3,222.66	6,267.86	9,180.13	10,875.03
12	Extraordinary Items (net of tax expense Rs.____)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	1,771.93	2,472.86	3,222.66	6,267.86	9,180.13	10,875.03
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	1,771.93	2,472.86	3,222.66	6,267.86	9,180.13	10,875.03
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	54,658.58
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	1.39	1.94	2.73	4.92	7.78	9.04
	b) Diluted	1.39	1.94	2.73	4.92	7.78	9.04
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	1.39	1.94	2.73	4.92	7.78	9.04
	b) Diluted	1.39	1.94	2.73	4.92	7.78	9.04


PART - II							
A	PARTICULARS OF SHAREHOLDING	31-Dec-2015	30-Sep-2015	31-Dec-2014	31-Dec-2015	31-Dec-2014	31-Mar-2015
1	Public share holdings						
	a. Number of shares	51,462,478	51,462,478	51,624,902	51,462,478	51,624,902	51,624,902
	b. Percentage of share holding	40.43%	40.43%	40.56%	40.43%	40.56%	40.56%
2	Promoters and promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	75,820,000	75,820,000	75,657,576	75,820,000	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	59.57%	59.57%	59.44%	59.57%	59.44%	59.44%
Particulars		3 months ended (31-12-2015)					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	-					
	Received during the quarter	46					
	Disposed of during the quarter	46					
	Remaining unresolved at the end of the quarter	-					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							<i>Rs. in lakhs</i>
PARTICULARS	Quarter ended			Nine months ended		Previous year ended	
	31-Dec-2015	30-Sep-2015	31-Dec-2014	31-Dec-2015	31-Dec-2014	31-Mar-2015	
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	
1	SEGMENT REVENUE						
	a) Manufacturing (CRAMS)	10,252.62	10,475.82	12,328.69	30,299.98	39,230.28	
	b) Services (DDDSS)	997.81	1,200.32	554.28	2,724.73	1,788.97	
	c) Research & Development	-	-	-	-	-	
	Net sales/income from operations	11,250.43	11,676.14	12,882.97	33,024.71	41,019.25	
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
	a) Manufacturing (CRAMS)	3,310.74	3,770.24	6,137.28	11,131.39	17,169.08	
	b) Services (DDDSS)	622.30	813.15	174.33	1,669.62	947.17	
	c) Research & Development	(1,516.97)	(1,506.27)	(1,469.96)	(4,616.85)	(4,058.80)	
	TOTAL	2,416.07	3,077.12	4,841.65	8,184.16	14,057.45	
	Less: (i) Interest	107.66	101.90	65.34	262.52	224.77	
	(ii) Other Un-allocable expenses net off	53.68	(87.47)	298.34	(24.53)	942.06	
	(iii) un-allocable Income	-	-	-	-	-	
	Profit Before Tax	2,254.73	3,062.69	4,477.97	7,946.17	12,890.62	
3	CAPITAL EMPLOYED (Segment Assets-Segment Liabilities)						
	a) Manufacturing (CRAMS)	40,455.95	36,350.56	30,723.12	40,455.95	30,723.12	
	b) Services (DDDSS)	3,314.19	3,460.06	3,170.05	3,314.19	3,170.05	
	c) Research & Development	239.23	351.84	841.37	239.23	841.37	
	d) Un-allocated	27,167.79	28,872.23	29,106.35	27,167.79	29,106.35	
	TOTAL	71,177.16	69,034.69	63,840.89	71,177.16	63,840.89	

Notes:

- 1) The above results were reviewed by the Audit Committee and approved by the Board of Directors' Meeting held on 12th February, 2016.
- 2) Corresponding previous period figures have been regrouped/ reclassified whenever necessary.
- 3) The above results were reviewed by Auditors.

For SUVEN LIFE SCIENCES LTD



Place : Hyderabad
Date: 12th February, 2016

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver



Ref No.LR/009/2015-16:

LIMITED REVIEW REPORT

To


The Board of Directors of
SUVEN LIFE SCIENCES LIMITED


We have reviewed the accompanying statement of unaudited financial results of SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No.5, Avenue 7, Banjara Hills, Hyderabad – 500034, for the period ended on 31.12.2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **KARVY & CO.,**
Chartered Accountants
(Firm Registration No.001757S)


(K. AJAY KUMAR)
PARTNER
M.No.021989



Place: Hyderabad
Date : 12/02/2016

News Release

Suven Revenue down by 4.96%; PAT down by 28.34% for the Third quarter ended December, 2015

HYDERABAD, INDIA (12th February, 2016) – Suven Life Sciences Limited, a biopharmaceutical company specialized in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12th February, 2016 at Hyderabad.

Financial Highlights for the 3rd Quarter ended December' 2015 (QoQ):

Growth in revenue	INR 1165 Mn vs Rs 1226 Mn - down by 4.96%
Growth in PAT	INR 177 Mn vs. Rs 247 Mn - down by 28.34%
Growth in EBIDTA	INR 286 Mn vs. Rs 365 Mn - down by 21.67%

Financial Highlights for the 9 months' period ended December' 2015:

Growth in revenue	INR 3451 Mn vs Rs 4150 Mn - down by 16.84%
Growth in PAT	INR 627 Mn vs. Rs 918 Mn - down by 31.72%
Growth in EBIDTA	INR 952 Mn vs. Rs 1415 Mn - down by 32.70%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of INR 462 Mn (13.38% on revenue) for the 9 months' period ended Dec' 2015.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com